Pegaptanib Sodium (Macugen) for Macular Degeneration
The FDA has approved pegaptanib sodium (Macugen - Pfizer/Eyetech) as an intravitreous injection for treatment of all subtypes of neovascular (wet) age-related macular degeneration (AMD). The only other approved treatment for this condition is photodynamic therapy with intravenous verteporfin (Visudyne), which is recommended only for patients with one subtype (predominantly classic) of neovascular AMD....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Pegaptanib Sodium (Macugen) for Macular Degeneration
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1212
Article Code: 1212c
Date: July 4, 2005
Volume: 47
Pages: 55-56
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1212
Article Code: 1212c
Date: July 4, 2005
Volume: 47
Pages: 55-56
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)